Drug Type Biological products |
Synonyms PF 06835375 |
Target |
Mechanism CXCR5 antagonists(C-X-C motif chemokine receptor 5 antagonists) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhasePhase 2 |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Purpura, Thrombocytopenic, Idiopathic | Phase 2 | US | 02 Feb 2022 | |
Purpura, Thrombocytopenic, Idiopathic | Phase 2 | AU | 02 Feb 2022 | |
Purpura, Thrombocytopenic, Idiopathic | Phase 2 | CA | 02 Feb 2022 | |
Purpura, Thrombocytopenic, Idiopathic | Phase 2 | CZ | 02 Feb 2022 | |
Purpura, Thrombocytopenic, Idiopathic | Phase 2 | HU | 02 Feb 2022 | |
Purpura, Thrombocytopenic, Idiopathic | Phase 2 | PL | 02 Feb 2022 | |
Purpura, Thrombocytopenic, Idiopathic | Phase 2 | GB | 02 Feb 2022 | |
Rheumatoid Arthritis | Phase 1 | US | 17 Nov 2017 | |
Systemic Lupus Erythematosus | Phase 1 | US | 17 Nov 2017 | |
Lupus Vulgaris | Phase 1 | - | - |